| --- | --- | |-----------|-------| | | | | | | | | | | | | | Q1 2024 | | | Financial | | | Results | | | Update | | | | | | | | | | | | | | | | | | May 1, 2024 | | | | | | | | | | | | | | | | | | | | 1 PROPRIETARY AND CONFIDENTIAL 2 Q1 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks | --- | --- | --- | |-------|-------|-------| | Presenter \nJoseph C. Papa | • | Topic(s) \nTransformation Plan Update | | President and CEO | | | | Rich Lindahl | • | Q1 2024 Financial Review | | EVP, CF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction o ...

EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS • First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range • First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million • Updates FY 2024 guidance GAITHERSBURG, Md., May 1, 2024—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President an ...

Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million  GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced the next phase of its new operational plan that consolidates operations, ...

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more ...

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility. "In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position," stated Joe Papa, president and CEO of Emergent. "Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive dev ...

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon r ...

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon re ...

Emergent BioSolutions (EBS) reported an adjusted loss of 77 cents per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of 33 cents. In the year-ago quarter, EBS reported adjusted earnings of 11 cents per share.Revenues in the quarter totaled $276.6 million, down 16% from the prior-year period’s level. The reported figure outpaced the Zacks Consensus Estimate of $247.6 million.The company's shares lost almost 16% in after-market trading on Mar 6, likely due to the earnings miss ...

公司业务 - Emergent是一家全球生命科学公司，专注于提供创新的应对意外、蓄意和自然发生的公共卫生威胁解决方案[202] - NARCAN®是Emergent的主要商业产品，是一种经FDA和加拿大卫生部批准的纳洛酮盐鼻喷剂，用于急救已知或疑似的阿片类药物过量[203] - Anthrasil®、BioThrax®、CYFENDUS®和Raxibacumab injection是Emergent的主要炭疽-医疗对策产品，用于治疗和预防炭疽病[205] - ACAM2000®、CNJ-016®和TEMBEXA®是Emergent的主要天花-医疗对策产品，用于预防和治疗天花病[206] - BAT®、Ebanga™、RSDL®和Trobigard®是Emergent的其他产品，用于治疗肉毒杆菌、埃博拉、化学战剂和神经毒剂[207] - Emergent的服务部门提供合同开发和制造服务，包括药物物质制造、药物产品制造和包装，以及开发服务[208] - Emergent通过销售旅行健康业务给Bavarian Nordic获得了2.702亿美元的现金收入，并可能获得高达80.0万美元的里程碑付款[209] - FDA批准了CYFENDUS®用于炭疽病的后暴露预防，Emergent获得了与BARDA的价值高达7.04亿美元的EbangaTM采购合同[209] - Emergent在2023年第三季度推出了NARCAN® OTC，扩大了销售渠道到零售药店和数字商务网站[210] 财务表现 - 公司通过销售NARCAN®鼻喷剂和其他商业产品实现营收，2023年NARCAN®销售额为4.875亿美元，同比增长30%[213] - MCM产品销售净额为4.472亿美元，较去年同期下降23%[216] - 2023年总营收为10.493亿美元，较去年同期下降6%[216] - 商业产品销售净额占总营收的比例较去年同期有所增加，达到47.4%[216] - 总营收中合同和赠款收入下降36%，为2.63亿美元[217] - 总分部营收净额为10.23亿美元，较去年同期下降5%[217] - 总分部毛利润为3.176亿美元，毛利率为31%[217] - 商业产品销售成本较去年同期增加31%，为2.103亿美元[217] - MCM产品销售成本较去年同期增加16%，为3.056亿美元[217] - 2023年12月31日，商业产品部门的收入为497.3百万美元，较2022年增长29%[224] - 2023年NARCAN®销售额增加了1.138亿美元，增长30%，达到4.875亿美元[225] - 2023年MCM产品销售额下降了1.025亿美元，降幅为35%，达到1.876亿美元[228] - 2023年服务部门的收入为78.5百万美元，较2022年下降了29%[230] - 合同和赠款收入在2023年下降了1.51亿美元，降幅为36%，达到2.63亿美元[234] 财务状况 - 截至2023年12月31日，现金及现金等价物为1.117亿美元，较2022年减少了83%[251] - 2023年经营活动净现金流为负2.063亿美元，较2022年增加了1.722亿美元[255] - 2023年投资活动净现金流为21.23亿美元，较2022年增加了5.936亿美元[255] - 2023年融资活动净现金流为负53.57亿美元，较2022年增加了10亿美元[255] - 截至2023年12月31日，公司固定和浮动利率债务总额为8.684亿美元，其中12个月内到期的债务为4.184亿美元[256] - 公司的未使用信贷额度为80.3百万美元[260] - 公司的固定租金支付义务为20.4百万美元，非可取消采购承诺为526.9百万美元[261]